Dafna Capital Management 13F annual report
Dafna Capital Management is an investment fund managing more than $414 billion ran by Nathan Fischel. There are currently 82 companies in Mr. Fischel’s portfolio. The largest investments include Spdr Sp Biotech Etf and Stereotaxis, together worth $66.2 billion.
$414 billion Assets Under Management (AUM)
As of 7th August 2024, Dafna Capital Management’s top holding is 445,005 shares of Spdr Sp Biotech Etf currently worth over $41.3 billion and making up 10.0% of the portfolio value.
In addition, the fund holds 13,680,554 shares of Stereotaxis worth $24.9 billion, whose value fell 29.5% in the past six months.
The third-largest holding is Merus N.V worth $24.2 billion and the next is Cytokinetics Inc worth $21.6 billion, with 398,100 shares owned.
Currently, Dafna Capital Management's portfolio is worth at least $414 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Dafna Capital Management
The Dafna Capital Management office and employees reside in Los Angeles, California. According to the last 13-F report filed with the SEC, Nathan Fischel serves as the CEO at Dafna Capital Management.
Recent trades
In the most recent 13F filing, Dafna Capital Management revealed that it had opened a new position in
UroGen Pharma Ltd and bought 469,000 shares worth $7.87 billion.
This means they effectively own approximately 0.1% of the company.
UroGen Pharma Ltd makes up
2.5%
of the fund's Health Care sector allocation and has decreased its share price by 33.9% in the past year.
The investment fund also strengthened its position in Spdr Sp Biotech Etf by buying
13,790 additional shares.
This makes their stake in Spdr Sp Biotech Etf total 445,005 shares worth $41.3 billion.
On the other hand, there are companies that Dafna Capital Management is getting rid of from its portfolio.
Dafna Capital Management closed its position in Perspective Therapeutics Inc on 14th August 2024.
It sold the previously owned 3,103,644 shares for $3.69 billion.
Nathan Fischel also disclosed a decreased stake in IDEAYA Biosciences by approximately 0.1%.
This leaves the value of the investment at $14.8 billion and 422,213 shares.
One of the average hedge funds
The two most similar investment funds to Dafna Capital Management are D'orazio & Associates and Adw Capital Management. They manage $414 billion and $414 billion respectively.
Nathan Fischel investment strategy
Dafna Capital Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 77.0% of
the total portfolio value.
The fund focuses on investments in the United States as
54.9% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
12% of the total holdings value.
On the other hand, large-cap stocks make up only 3.7% of the portfolio.
The average market cap of the portfolio companies is close to $1.79 billion.
The complete list of Dafna Capital Management trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Spdr Sp Biotech Etf |
3.20%
445,005
|
$41,256,414,000 | 9.96% |
| Stereotaxis, Inc. |
No change
13,680,554
|
$24,898,608,000 | 6.01% |
| Merus N.V |
8.03%
409,445
|
$24,226,861,000 | 5.85% |
| Cytokinetics Inc |
No change
398,100
|
$21,569,058,000 | 5.21% |
| Revolution Medicines Inc |
No change
511,894
|
$19,866,606,000 | 4.80% |
| IDEAYA Biosciences, Inc. |
5.41%
422,213
|
$14,823,898,000 | 3.58% |
| Atricure Inc |
135.83%
639,173
|
$14,553,969,000 | 3.51% |
| Ishares Nasdaq Biotech Indx |
No change
102,500
|
$14,069,150,000 | 3.40% |
| Syndax Pharmaceuticals Inc |
0.38%
657,074
|
$13,489,729,000 | 3.26% |
| Blueprint Medicines Corp |
1.87%
104,763
|
$11,291,356,000 | 2.73% |
| Ascendis Pharma A/S |
12.44%
80,972
|
$11,042,961,000 | 2.67% |
| Xenon Pharmaceuticals Inc |
No change
273,739
|
$10,673,084,000 | 2.58% |
| Viking Therapeutics Inc |
2.58%
189,117
|
$10,025,092,000 | 2.42% |
| Neurocrine Biosciences, Inc. |
No change
71,615
|
$9,859,237,000 | 2.38% |
| KalVista Pharmaceuticals Inc |
No change
806,973
|
$9,506,142,000 | 2.30% |
| Day One Biopharmaceuticals I |
No change
666,463
|
$9,183,860,000 | 2.22% |
| Kura Oncology Inc |
2.63%
423,500
|
$8,719,865,000 | 2.11% |
| Tandem Diabetes Care Inc |
20.91%
204,208
|
$8,227,540,000 | 1.99% |
| Morphic Holding Inc |
No change
231,748
|
$7,895,654,000 | 1.91% |
| UroGen Pharma Ltd |
Opened
469,000
|
$7,869,820,000 | 1.90% |
| Biohaven Ltd |
84.22%
218,730
|
$7,592,118,000 | 1.83% |
| Dexcom Inc |
No change
65,552
|
$7,432,286,000 | 1.79% |
| Axogen Inc. |
No change
935,894
|
$6,775,873,000 | 1.64% |
| Edgewise Therapeutics Inc |
5.23%
290,197
|
$5,226,448,000 | 1.26% |
| Larimar Therapeutics, Inc. |
2.50%
639,974
|
$4,639,812,000 | 1.12% |
| Biocryst Pharmaceuticals Inc. |
0.70%
704,500
|
$4,353,810,000 | 1.05% |
| Century Therapeutics Inc |
30.35%
1,704,232
|
$4,345,792,000 | 1.05% |
| Alector, Inc. |
No change
912,928
|
$4,144,693,000 | 1.00% |
| 2seventy Bio Inc |
12.74%
1,050,709
|
$4,045,230,000 | 0.98% |
| Arcus Biosciences Inc |
9.28%
253,217
|
$3,856,495,000 | 0.93% |
| Perspective Therapeutics Inc |
Closed
3,103,644
|
$3,693,336,000 | |
| Galapagos NV |
No change
130,175
|
$3,225,737,000 | 0.78% |
| Insulet Corporation |
No change
15,900
|
$3,208,620,000 | 0.77% |
| Keros Therapeutics, Inc. |
No change
67,754
|
$3,096,358,000 | 0.75% |
| Acelyrin Inc |
242.38%
693,609
|
$3,058,816,000 | 0.74% |
| Alkermes plc |
Opened
120,700
|
$2,908,870,000 | 0.70% |
| Stoke Therapeutics, Inc. |
43.05%
207,427
|
$2,802,339,000 | 0.68% |
| Astria Therapeutics Inc |
22.80%
274,165
|
$2,494,902,000 | 0.60% |
| Bicycle Therapeutics plc |
No change
122,200
|
$2,473,328,000 | 0.60% |
| Perspective Therapeutics Inc |
Opened
231,634
|
$2,309,391,000 | 0.56% |
| Accuray Inc |
No change
1,222,358
|
$2,224,692,000 | 0.54% |
| iTeos Therapeutics, Inc. |
46.47%
144,360
|
$2,142,302,000 | 0.52% |
| Ars Pharmaceuticals Inc |
No change
239,194
|
$2,035,541,000 | 0.49% |
| MediWound Ltd |
34.05%
124,479
|
$1,931,914,000 | 0.47% |
| Brainsway Ltd. |
No change
297,655
|
$1,806,766,000 | 0.44% |
| Inogen Inc |
No change
208,790
|
$1,697,463,000 | 0.41% |
| Immatics Nv |
No change
145,000
|
$1,684,900,000 | 0.41% |
| Regulus Therapeutics Inc |
16.38%
895,200
|
$1,597,932,000 | 0.39% |
| BioNTech SE |
Closed
17,000
|
$1,568,250,000 | |
| ProQR Therapeutics N.V |
No change
905,582
|
$1,503,266,000 | 0.36% |
| COMPASS Pathways plc |
No change
243,210
|
$1,468,988,000 | 0.35% |
| Allogene Therapeutics Inc |
Opened
605,100
|
$1,409,883,000 | 0.34% |
| Mineralys Therapeutics Inc |
32.22%
119,000
|
$1,392,300,000 | 0.34% |
| Aquestive Therapeutics Inc |
6.00%
530,000
|
$1,378,000,000 | 0.33% |
| Lineage Cell Therapeutics In |
1.14%
1,350,708
|
$1,347,061,000 | 0.33% |
| Alto Neuroscience Inc |
1,100.00%
120,000
|
$1,282,800,000 | 0.31% |
| Gossamer Bio, Inc. |
No change
1,409,262
|
$1,269,604,000 | 0.31% |
| Immunovant Inc |
62.89%
47,916
|
$1,264,982,000 | 0.31% |
| Sage Therapeutics Inc |
Opened
116,200
|
$1,261,932,000 | 0.30% |
| Autolus Therapeutics plc |
60.00%
346,667
|
$1,206,401,000 | 0.29% |
| Centessa Pharmaceuticals Plc |
Opened
122,882
|
$1,109,624,000 | 0.27% |
| Tourmaline Bio Inc |
Opened
75,982
|
$977,129,000 | 0.24% |
| Sutro Biopharma Inc |
1.35%
329,579
|
$965,666,000 | 0.23% |
| Procept Biorobotics Corp |
74.55%
13,994
|
$854,893,000 | 0.21% |
| PolyPid Ltd. |
0.32%
184,846
|
$794,838,000 | 0.19% |
| Compugen Ltd |
7.44%
462,202
|
$776,499,000 | 0.19% |
| Nyxoah S A |
Opened
108,108
|
$753,513,000 | 0.18% |
| Adicet Bio Inc |
No change
600,000
|
$726,000,000 | 0.18% |
| Acrivon Therapeutics Inc |
7.61%
121,351
|
$703,836,000 | 0.17% |
| Syros Pharmaceuticals Inc. |
No change
135,850
|
$700,986,000 | 0.17% |
| ADC Therapeutics SA |
Opened
204,081
|
$644,896,000 | 0.16% |
| Terns Pharmaceuticals Inc |
Opened
86,000
|
$585,660,000 | 0.14% |
| Neuronetics Inc |
No change
313,717
|
$564,691,000 | 0.14% |
| Aprea Therapeutics, Inc. |
No change
137,174
|
$558,298,000 | 0.13% |
| Neurogene Inc |
Opened
11,000
|
$400,290,000 | 0.10% |
| Masimo Corp |
No change
3,000
|
$377,820,000 | 0.09% |
| Adaptimmune Therapeutics Plc |
No change
341,064
|
$332,503,000 | 0.08% |
| Oric Pharmaceuticals, Inc. |
Opened
36,000
|
$254,520,000 | 0.06% |
| Vigil Neuroscience Inc |
Closed
71,815
|
$244,889,000 | |
| Foghorn Therapeutics Inc. |
Opened
41,850
|
$240,638,000 | 0.06% |
| Nevro Corp |
No change
28,000
|
$235,760,000 | 0.06% |
| Structure Therapeutics Inc |
Opened
5,000
|
$196,350,000 | 0.05% |
| Karyopharm Therapeutics Inc |
No change
192,678
|
$167,167,000 | 0.04% |
| Spero Therapeutics Inc |
No change
125,000
|
$162,500,000 | 0.04% |
| Compass Therapeutics Inc |
No change
116,882
|
$116,882,000 | 0.03% |
| No transactions found | |||
| Showing first 500 out of 85 holdings | |||
Hedge funds similar to Dafna Capital Management
- Bienville Capital Management
- Kirr Marbach & Co in/
- Greenspring Advisors
- Ikarian Capital
- Ashton Thomas Securities
- First National Bank Of Mount Dora, Trust Investment Services
- Adw Capital Management
- D'orazio & Associates
- Manhattan West Asset Management
- Alphacore Capital
- Franchise Capital Ltd
- Blume Capital Management
- Wpwealth LL.P.
- Northstar Asset Management Co